Previous close | 0.2400 |
Open | 0.2400 |
Bid | 0.0000 |
Ask | 1.0500 |
Strike | 240.00 |
Expiry date | 2023-06-16 |
Day's range | 0.2400 - 0.2400 |
Contract range | N/A |
Volume | |
Open interest | 17 |
UnitedHealth Group, The Cigna Group, Humana, Centene Corporation and Molina Healthcare are part of the Zacks Industry Outlook article.
OKLAHOMA CITY, June 08, 2023--Leading health and wellness company Humana Inc. (NYSE: HUM) has been recommended by the Oklahoma Health Care Authority (OHCA) to deliver health care coverage to Medicaid beneficiaries across the state, anticipated to start in early to mid-2024. Humana’s Medicaid division, Humana Healthy Horizons, will administer the coverage in Oklahoma.
The Medical-HMO industry is witnessing growth in customer base and an active M&A strategy. However, high technology expenses and medical personnel shortage raise concerns. UNH, CI, HUM, CNC and MOH are likely to navigate the industry storms.
Humana's (HUM) CenterWell business focuses on providing a better healthcare experience through clubbing primary care, home health and pharmacy services.
LOUISVILLE, Ky., June 06, 2023--CenterWell Senior Primary Care propels primary care network to 250 centers.
Cigna (CI) and Humana (HUM) are well-positioned to expand in the promising HMO space. Let's try to find out which one fares better via comparative evaluation.
Humana (HUM) remains well-poised for growth, attributable to a growing customer base, numerous contract wins and solid cash-generating abilities.
These partnerships will equip Humana (HUM) with the means to deploy advanced clinical programs that can reduce hospitalizations for the members.
LOUISVILLE, Ky., May 11, 2023--Humana to partner with two national Durable Medical Equipment organizations.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Select Medical (SEM) expects revenues to be within the range of $6.5-$6.7 billion in 2023, indicating a rise of 4.8% from the 2022 figure of $6.3 billion.
LOUISVILLE, Ky. & NORTH PALM BEACH, Fla., May 04, 2023--Humana and Longevity Health partner to expand access to Special Needs Plans for Medicare beneficiaries in more than a dozen states.
LOUISVILLE, Ky., May 01, 2023--Humana Inc. (NYSE: HUM) announced today that Bruce D. Broussard, President and Chief Executive Officer, and Susan M. Diamond, Chief Financial Officer, will make a presentation to investors at the BofA Securities Healthcare Conference on Tuesday, May 9, 2023, at 8:40 a.m. Pacific time.
The average brokerage recommendation (ABR) for Humana (HUM) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Molina Healthcare's (MOH) Q1 results reflect strong performance in the Medicaid and Medicare segments. Meanwhile, the elevated expense level partially offset the positives.
Tenet Healthcare's (THC) first-quarter 2023 results gain on increased patient volumes. Management presently expects adjusted EPS within $4.92-$6.09 in 2023, up from the prior view of $4.68-$5.85.
Humana (HUM) expects adjusted EPS to be at least $28.25 in 2023, up from the previous guidance of $28 per share.
(Reuters) -Humana Inc raised its annual adjusted profit forecast on Wednesday after lower medical costs in the firm's government-backed health insurance business helped it beat profit estimates for the first quarter. The company's upbeat outlook contrasts the uncertainty around 2024 earnings for health insurers staring at the end of COVID-related insurance protection measures and potential declines in government payouts for some plans. Investors have also been worried about health insurers including UnitedHealth and Elevance recording benign medical claims costs even as hospitals and medical device makers see a recovery in non-urgent procedures and routine checkups.
LOUISVILLE, Ky., April 26, 2023--Humana Inc. (NYSE: HUM) today reported consolidated pretax results and net earnings per share (EPS) for the quarter ended March 31, 2023 (1Q23) versus the quarter ended March 31, 2022 (1Q22) as noted in the tables below.
Humana, Viatris, agilon health and Cano Health are included in this Analyst Blog.
Investing.com -- Stocks in focus in premarket trade on Wednesday, April 26th. Please refresh for updates.
Ecolab's (ECL) first-quarter results are likely to reflect continued strength in its Global Industrial segment.
Growing patient volumes, admissions, health awareness and technological improvement in the first quarter are likely to have aided healthcare players like Humana (HUM), Viatris (VTRS), agilon health (AGL) and Cano Health (CANO).
Humana (HUM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Humana's (HUM) first-quarter results are likely to reflect surging premiums and investment income.